Comparison
Retatrutide vs Tirzepatide: What the Research Compares
Two incretin-class compounds at different approval stages. One is approved; one is investigational. A measured reading of what the published data actually say about each.
Start here — two different stages, not two products
Retatrutide vs tirzepatide is the most-searched comparison in this compound class, and the most important thing to state plainly is that these two compounds are at fundamentally different regulatory stages. Tirzepatide is an approved drug — FDA-approved for type 2 diabetes and, in a higher-dose formulation, for obesity management. Retatrutide is investigational — not approved anywhere in the world, not available by prescription, currently in Phase 3 trials.
This page compares them on mechanism and the published Phase 2 data. Cross-trial comparisons are inherently limited: different populations, different trial durations, different protocols. The only rigorous comparison will come from the head-to-head Phase 3 trial NCT06662383, which is ongoing and has not published results [9].
Neither compound should be described in terms of brand names. This site uses only the International Nonproprietary Names: retatrutide and tirzepatide.
Mechanism: dual agonist versus triple agonist
Tirzepatide is a GIP/GLP-1 dual agonist — a single molecule that activates both the GIPR and GLP-1R. It was the first dual incretin agonist approved by the FDA and demonstrated weight-loss figures (approximately 15-22% in the pivotal SURPASS and SURMOUNT trials) substantially higher than prior single GLP-1 agonists.
Retatrutide adds a third receptor: the glucagon receptor (GCGR). This distinction matters mechanistically. GCGR activation increases hepatic (liver) lipid oxidation and thermogenesis (the body generating heat from stored energy), adding an energy-expenditure dimension that the dual-agonist class does not engage. Whether this third arm meaningfully adds to the therapeutic benefit — versus adding primarily to side effects — is what Phase 3 head-to-head data will determine.
Structurally, both compounds use fatty-acid acylation to extend their half-lives to approximately one week, supporting once-weekly dosing. Tirzepatide's half-life is approximately 5 days; retatrutide's is approximately 6 days [4]. Cryo-EM structural data show retatrutide's relative potency at GIPR is 8.9x the native hormone (super-potent), while tirzepatide also exhibits GIPR super-potency — the similar GIPR design may contribute to the comparable initial efficacy figures [3].
Phase 2 weight-loss data: what the numbers show
Direct cross-trial comparison should be made cautiously. The most cited figures are:
Retatrutide (Jastreboff 2023, NEJM): 48-week Phase 2 obesity trial, 12 mg once weekly — mean body-weight change -24.2% (vs -2.1% placebo) [1].
Tirzepatide (SURMOUNT-1, Jastreboff 2022, NEJM): 72-week Phase 3 obesity trial, 15 mg once weekly — mean body-weight change -22.5% (vs -2.4% placebo). Approved and confirmed at Phase 3 scale.
The numerical difference — approximately 1.7 percentage points — is within the margin of uncertainty for cross-trial comparisons. Retatrutide's figure comes from a Phase 2 trial of 338 participants at 48 weeks; tirzepatide's comes from a Phase 3 trial of 2,539 participants at 72 weeks. Different sample sizes, different durations, and different populations mean the comparison is preliminary.
In type 2 diabetes: retatrutide 12 mg reduced HbA1c by -2.02% at 24 weeks in a Phase 2 trial [2]. For context, published tirzepatide Phase 3 data showed HbA1c reductions of approximately -2.0-2.3% in the SURPASS program — broadly similar magnitudes, though again from different trial designs.
For retatrutide results in tabular form, see the results page.
The head-to-head Phase 3 trial — NCT06662383
The active-comparator trial (NCT06662383) directly randomizes participants to receive either retatrutide or tirzepatide on a once-weekly subcutaneous schedule, providing the only methodology capable of producing a valid head-to-head comparison [9]. It is the first such head-to-head trial between these two compounds and, when it reports, will produce the most definitive answer available to the retatrutide vs tirzepatide question.
As of mid-2026, the trial was ongoing and had not published results. Until those data are available, any claim that retatrutide is meaningfully superior or inferior to tirzepatide rests on cross-trial comparisons that do not meet the evidentiary standard the question deserves.
The Retatrutide research page covers the full Phase 1/2 literature in greater depth, including the mechanistic cryo-EM data and the recent 2024-2025 lipid and kidney findings.
Regulatory status: the critical asymmetry
Tirzepatide is FDA-approved. It has a labeled indication, a licensed formulation, prescribed dose schedules, a prescribing information document, and an approved safety profile based on Phase 3 outcomes data. It is available by prescription and manufactured under GMP (Good Manufacturing Practice — the regulatory standards for pharmaceutical production) with verified identity, purity, and sterility.
Retatrutide is none of these things. It is investigational. Its Phase 2 data are compelling enough to have advanced it into Phase 3, but Phase 3 trials exist precisely because Phase 2 results do not always replicate at scale. Until the TRIUMPH program reports, retatrutide's efficacy and long-term safety profile remain in-progress determinations.
The retatrutide vs tirzepatide question, framed practically: tirzepatide is a finished, regulated, approved medicine; retatrutide is a clinical-stage compound that has produced strong Phase 2 signals but has not yet completed the regulatory process.